Quanterix is trying to turn its lab testing tools into a bigger, stickier business by pairing its core platform with Akoya and making its consumables work with equipment many labs already use. The upside hinges on wider adoption in research and early disease detection, but falling sales, big spending, and a tricky integration could keep profits out of reach.Read more
Quanterix is betting that its ultra-sensitive blood testing platform can become a go-to tool for spotting disease earlier, helped by new product upgrades and a push into tissue-based biology through a recent acquisition. The upside comes from more recurring sales and new drug-company partnerships, but the story depends on turning around a business that’s still losing money amid tighter research budgets, tough integration work, and rising competition.Read more
Quanterix rides big long-term demand for early disease detection, but near-term customer budget pressures and heavy spending make the path to steady growth and profits uncertain. The key question is whether the Akoya deal and new tech can broaden its reach and cut costs before tougher competition and regulation squeeze the business.Read more
No trending discussion available.
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
